Gastroretentive mucoadhesive tablet of lafutidine for controlled release and enhanced bioavailability

Drug Delivery

Volumn 22, Issue 3, 2015, Pages 312-319

  Patil, Satish ^a   Talele, Gokul S ^b  

^a Alkem Research Centre   (India)

^b NSG Nasik   (India)

Author keywords

In vitro and in vivo study; Lafutidine; Mucoadhesive; Sustained release

Indexed keywords

ALGINIC ACID; KARAYA GUM; LAFUTIDINE; MAGNESIUM STEARATE; TALC; XANTHAN; ACETAMIDE DERIVATIVE; BACTERIAL POLYSACCHARIDE; DELAYED RELEASE FORMULATION; GLUCURONIC ACID; HEXURONIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; TABLET; TISSUE ADHESIVE;

ALBINO RABBIT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EVALUATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MECHANISM; DRUG RETENTION; DRUG STABILITY; DRUG STORAGE; DRY POWDER; GASTROINTESTINAL TRACT; HUMIDITY; IN VITRO STUDY; IN VIVO STUDY; LAG TIME; MUCOADHESION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RABBIT; STOMACH RADIOGRAPHY; STOMACH ULCER; TABLET; ADHESION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG RELEASE; GASTRIC MUCOSA; INFRARED SPECTROSCOPY; METABOLISM; PIG;

ACETAMIDES; ADHESIVENESS; ALGINATES; ANIMALS; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG LIBERATION; GASTRIC MUCOSA; GLUCURONIC ACID; HEXURONIC ACIDS; HISTAMINE H2 ANTAGONISTS; IN VITRO TECHNIQUES; KARAYA GUM; PIPERIDINES; POLYSACCHARIDES, BACTERIAL; PYRIDINES; RABBITS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SWINE; TABLETS; TISSUE ADHESIVES;

EID: 84930443926     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.877099     Document Type: Article

References (26)

1. Arora S, Ali J, Ahuja A, et al. (2005). Floating drug Delivery systems: a review. AAPS PharmSciTech 6:E372-90
2. Atyabi F, Sharma H, Mohammad H, Fell J. (1996). In vitro evaluation of a novel gastro retentive formulation based on ion exchange resins. J Control Release 42:105-13
3. Bhupesh D, Raghuram C. (2010). An open-label randomized cross-over bioequivalence study of lafutidine 10 mg unDer fasting condition. World J Gastrointest Pharmacol Ther 1:112-18
4. Caldwell L, Gardner R, Cargill R, et al. (1988). Drug Delivery Device which can be retained in the stomach for a controlled period of times. US patents, 30th August 1988; 4, 767, 627
5. Chavanpatil MD, Jain P, Chaudhari S, et al. (2006). Novel sustained release, swellable bioadhesive gastroretentive drug Delivery system for ofloxacin. Int J Pharm 316:89-92
6. Chien Y. (1992). Novel drug Delivery systems. 2nd ed. New York: Marcel Dekker Inc., 171-6
7. Desai S, Bolton S. (1993). A floating controlled-release drug Delivery system: in vitro-in vivo evaluation. Pharm Res 10:1321-5
8. Dollery C. (1999). Therapeutic drugs. Edinburgh, Scotl: Churchil Livingstone, C113YC117
9. Dorozynski P, Jachowicz R, Kulinowski P, et al. (2004). The macromolecular polymers for the preparation of hydrodynamically balanced systems-methods of evaluation. Drug Dev Ind Pharm 30:947-57
10. Gandhi RB, Robinson JR. (1998). Bioadhesion in drug Delivery. Ind J Pharm Sci 50:145-52
11. Gershon S, PaDer M, Balsam M, et al. (1972). Cosmetics science and technology. New York: Wiley-Interstice, 423
12. Gibaldi M, Feldman S. (1967). Establishment of sink conditions in dissolution rate Determinations. Theoretical consiDerations and application to nondisintegrating dosage forms. J Pharm Sci 56: 1238-42
13. Higuchi T. (1963). Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52:1145-9
14. Hixson AW, Crowell JH. (1931). DepenDence of reaction velocity upon surface agitation. Ind Eng Chem 23:923-93
15. Ikawa K, Shimatani T, Hayato S, et al. (2007). Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine. Biol Pharm Bull 30:1003-6
16. International Conference on Harmonization Steering Committee (1999). Q1A-Stability testing of new drug substances and products
17. Korsmeyer R, Gurny R, Peppas N. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15:25-35
18. Lachman L, Hebert AL, Joseph LK. (1987). Theory and practice of pharmacy. 3rd ed. Varghese Publication House, 430-4
19. Mathews BR. (1999). Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm 25:831-56
20. Nokano M, Ogata A. (1984). Examination of natural gums as matrices for sustained release of Theophylline. Chem Pharm Bul 32:782-5
21. OnoDera S, Shibata M, Tanaka M, et al. (1995). Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats. Jpn J Pharmacol 68:161-73
22. Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110-11
23. Rosa M, Zia H, RhoDes T. (1994). Dosing testing in vitro bioadhesive floating drug Delivery system for oral application. Int J Pharm 105: 65-70
24. Singh BN, Kim KH. (2000). Floating drug Delivery systems: an approach to oral controlled drug Delivery via gastric retention. J Control Release 63:235-59
25. Suvarna K, Manisha S, Sugandha V. (2012). Development and validation of an UV spectrophotometric method for estimation of Lafutidine in bulk and tablet. In: contemporary investigation and observation in pharmacy, 1:5-8
26. Whitehead L, Fell JT, Collett JH, et al. (1998). Floating dosage forms: an in vivo study Demonstrating prolonged gastric retention. J Control Release 55:3-12